title: Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema.
authors.affiliation: Retina Consultants of Alabama, Birmingham 35233, USA.
authors.forename: John O
authors.initials: JO
authors.lastname: Mason
authors.forename: Michael A
authors.initials: MA
authors.lastname: Albert
authors.forename: Rachel
authors.initials: R
authors.lastname: Vail
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007267:Injections; D019654:Lens Implantation, Intraocular / Q000009:adverse effects; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification / Q000009:adverse effects; D019591:Pseudophakia / Q000188:drug therapy* / Q000209:etiology; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology; D014822:Vitreous Body
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab